Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 7, 2006, Pages 1196-1201

  Yoon, Su Jung ^a   Pae, Chi Un ^b   Kim, Dai Jin ^c   Namkoong, Kee ^d   Lee, Eun ^e   Oh, Dong Yul ^f   Lee, Young Sik ^g   Shin, Dong Hwan ^h   Jeong, Young Cheol ⁱ   Kim, Joon Hong ^j   Choi, Sung Bin ^k   Hwang, In Bok ^l   Shin, Young Chul ^m   Cho, Sung Nam ⁿ   Lee, Hae Kook ^o   Lee, Chung Tai ^o  

^a St Paul's Hospital   (South Korea)

^b Kangnam St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e National Health Insurance Corporation   (South Korea)

^f Catholic Kwandong University   (South Korea)

^g Chung Ang University College of Medicine   (South Korea)

^h Hong Seong Medical Center   (South Korea)

ⁱ Bae Sung Hospital   (South Korea)

^j Keyo Hospital ^*  (South Korea)

^k Keyo Hospital   (South Korea)

^l Dasarang Alcohol Hospital   (South Korea)

^m Sungkyunkwan University School of Medicine   (South Korea)

ⁿ Bugok National Hospital   (South Korea)

^o Uijeongbu St Mary's Hospital   (South Korea)

more..

Author keywords

Alcohol dependence; Craving; Depressive disorder; Mirtazapine

Indexed keywords

ANXIOLYTIC AGENT; HYPNOTIC AGENT; MIRTAZAPINE;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MOOD; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; RATING SCALE; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ALCOHOLISM; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33747257005     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.02.018     Document Type: Article

References (33)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
2. Anton R.F., Moak D.H., and Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19 (1995) 92-99
3. Bagby R.M., Ryder A.G., and Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 27 (2002) 250-257
4. Bahk W.M., Pae C.U., Tsoh J., Chae J.H., Jun T.Y., Chul-Lee, et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum Psychopharmacol 17 (2002) 341-344
5. Brown S.A., and Schuckit M.A. Changes in depression among abstinent alcoholics. J Stud Alcohol 49 (1988) 412-417
6. Brown S.A., Irwin M., and Schuckit M.A. Changes in anxiety among abstinent male alcoholics. J Stud Alcohol 52 (1991) 55-61
7. Brown S.A., Inaba R.K., Gillin J.C., Schuckit M.A., Stewart M.A., and Irwin M.R. Alcoholism and affective disorder: clinical course of depressive symptoms. Am J Psychiatry 152 (1995) 45-52
8. Cho M.J., Hahm B.J., Kim J.K., Park K.K., Chung E.K., Suh T.W., et al. Korean Epidemiologic Catchment Area (KECA) Study for psychiatric disorders prevalence of specific psychiatric disorders. J Kor Neuropsychiatr Assoc 43 (2004) 470-480
9. Chung M.Y., Min K.H., Jun Y.J., Kim S.S., Kim W.C., and Jun E.M. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 19 (2004) 489-494
10. Connor K.M., Davidson J.R., Weisler R.H., and Ahearn E. A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol 14 (1999) 29-31
11. Cornelius J.R., Salloum I.M., Haskett R.F., Ehler J.G., Jarrett P.J., Thase M.E., et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 24 (1999) 111-114
12. Crockford D.N., and White W.D. Mirtazapine for alcohol dependence: a case report. J Clin Psychiatry 66 (2005) 540
13. Crum R.M., Storr C.L., Chan Y., and Ford D.E. Sleep disturbance and risk for alcohol-related problems. Am J Psychiatry 161 (2004) 1197-1203
14. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 10 Suppl 4 (1995) 19-23
15. Guy W. ECDEU assessment manual for psychopharmacology, revised (1976), National Institute of Mental Health, Rockville, MD 76-338 DHEW Pub. No. (ADM)
16. Hamilton M. The assessment of anxiety state by rating. Br J Med Psychol 32 (1959) 50-55
17. Hamilton M. The rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
18. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 10 Suppl 4 (1995) 25-35
19. Kim D.J., Yoon S.J., Choi B., Kim T.S., Woo Y.S., Kim W., et al. Increased fasting plasma ghrelin levels during alcohol abstinence. Alcohol Alcohol 40 (2005) 76-79
20. Kranzler H.R., Manson B., and Modesto-Lowe V. Prevalence, diagnosis, and treatment of comorbid mood disorders and alcoholism. In: Kranzler H.R., and Rounsaville B. (Eds). Dual diagnosis and treatment (1998), Marcel Dekker, New York 107-136
21. LeMarquand D., Pihl R.O., and Benkelfat C. Serotonin and alcohol intake, abuse and dependence: clinical evidence. Biol Psychiatry 36 (1994) 326-337
22. Liappas J., Paparrigopoulos T., Malitas P., Tzavellas E., and Christodoulou G. Mirtazapine improves alcohol detoxification. J Psychopharmacol 18 (2004) 88-93
23. Liappas J., Paparrigopoulos T., Tzavellas E., and Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 55-60
24. McBride W.J., Lovinger D.M., Machu T., Thielen R.J., Rodd Z.A., Murphy J.M., et al. Serotinin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism. Alcohol Clin Exp Res 28 (2004) 257-267
25. McGrath P.J., Nunes E.V., Stewart J.W., Goldman D., Agosti V., Ocepek-Welikson K., et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 53 (1996) 232-240
26. Moak D.H., Anton R.F., Latham P.K., Voronin K.E., Waid R.L., and Durazo-Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol 23 (2003) 553-562
27. Montgomery S.A. Safety of mirtazapine: a review. Int Clin Psychopharmacol 10 Suppl 4 (1995) 37-45
28. Potgieter A.S., Deckers F., and Geerlings P. Craving and relapse measurement in alcoholism. Alcohol Alcohol 34 (1999) 254-260
29. Schuckit M.A. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64 (1996) 669-676
30. Shoaf S.E., and Linnoila M. Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacol Bull 27 (1991) 577-594
31. Tabakoff B., and Hoffman P.L. Neurochemical effects of alcohol. In: Frances R.J., and Miller S.I. (Eds). Clinical textbook of addictive disorders (1991), Guilford Press, New York 501-525
32. Thase M.E., Nierenberg A.A., Keller M.B., Panagides J., and Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 62 (2001) 782-788
33. Torrens M., Fonseca F., Mateu G., and Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 78 (2005) 1-22